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Abstract 
 
Modulation of the immune response plays an important role in the natural history of renal 
cell carcinoma.  Spontaneous regression of metastases has been well documented in a 
small percentage of patients after they undergo de-bulking nephrectomy without any 
additional systemic intervention.  The only logical explanation for these observations is 
“resetting” of the balance between tumor and the host immune system that, having been 
overwhelmed by the tumor burden, is able to function better after tumor de-bulking.  
Attempts to modulate the activity of the immune system “on demand” have included the 
use of vaccines, cytokines/lymphokines, adoptive cell transfer, monoclonal antibodies and 
most recently manipulation of immune checkpoint inhibitors.  Here we review the data for 
infusional interleukin-2 in the management of advanced renal cell carcinoma and its role in 
current clinical practice. Copyright: The Authors. 
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Introduction 
 
 
 
Spontaneous regression of metastatic renal 
cell carcinoma has been reported in a small 
percentage of patients after de-bulking 
nephrectomy without any additional 
systemic intervention (1-3). This is thought 
to be the result of “resetting” of the host 
immune system that had been 
overwhelmed by the tumor burden. Hence, 
immunotherapy has been the mainstay of 
treatment for advanced renal cell 
carcinoma until the introduction of 
targeted therapies. Interleukin 2 (IL-2) was 
approved by the USFDA in 1992 for the 
treatment of advanced renal cell 
carcinoma.  
Interleukin-2  
Demonstration that T lymphocytes could 
be grown in vitro, only in the presence of 
conditioned medium from 
phytohemagglutinin (PHA)-stimulated 
human blood lymphocytes (4), led to the 
discovery of a T cell growth factor 
subsequently designated IL-2 (5,6,7).  T 
lymphocytes grown in IL-2 containing 
culture were shown to have the ability to 
kill tumor cells in vitro (8).  IL-2 activated 
human peripheral blood lymphocytes 
showed lysis of natural killer-resistant 
fresh solid tumor cells - these were termed 
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LAK cells (9).  IL-2 was deemed to be 
necessary and sufficient for T cell growth 
and activation.  In vivo animal studies 
demonstrated that adoptive 
immunotherapy with transfer of syngeneic 
LAK cells generated in vitro, using IL-2, 
could eliminate natural, killer-resistant, 
established pulmonary melanoma and 
sarcoma metastases (10, 11).  IL-2 was 
shown to stimulate in vivo proliferation of 
adoptively transferred LAK cells (12), and 
systemic administration of high-dose IL-2 
without adoptive T cell transfer was shown 
to cause regression of established 
pulmonary metastases and subcutaneous 
tumors, proving that LAK cells could be 
generated in vivo (13). The cDNA coding for 
IL-2 was cloned and was shown to consist 
of 153 amino acids with a molecular weight 
of 15,420 daltons (14).  Availability of IL-2 
in large quantities made clinical trials 
possible.  Rosenberg et al. reported their 
experience in 25 treatment-resistant 
patients with advanced cancer, who were 
treated with a combination of LAK cells and 
interleukin-2.  These included patients 
with malignant melanoma, colorectal 
cancer, sarcoma, renal cell carcinoma, 
non-small cell lung cancer and esophageal 
cancer.  Eleven out of 25 patients had 
marked tumor regression; one patient with 
metastatic melanoma had a complete 
remission while 10 partial responses were 
observed, thus establishing proof of the 
principle that manipulation of the immune 
system using high-dose IL-2 could be 
performed safely and would induce 
significant clinically relevant responses 
(15). 
The discovery and availability of IL-2 for 
clinical use was pivotal in bringing an 
immunotherapeutic modality to the 
forefront (16).  Given that immune-
mediated regression had been observed in 
patients with renal cell carcinoma and the 
fact that renal cell carcinoma does not 
respond to chemotherapy, the earliest 
clinical investigations with IL-2, carried out 
at the NIH Surgery Branch, included renal 
cell carcinoma.  A progress report on the 
treatment of 157 patients with advanced 
cancer, using LAK cells and IL-2 or high-
dose IL-2 alone, included 36 patients with 
renal cell carcinoma.  An impressive 33% 
response rate was observed: 4/36 had a 
complete response and 8/36 had a partial 
response (≥ 50% decrease in sum of the 
products of the perpendicular diameters of 
all lesions).  An additional 7/36 patients 
experienced a minor response (25 to 49% 
decrease in sum of the products).  Most of 
the patients who had a complete response 
had lung metastases (17).  
High-dose IL-2 in RCC  
Further work at the NCI Surgery Branch 
reported their experience in 283 patients 
with metastatic melanoma or metastatic 
renal cell cancer treated from September 
1985 through December 1992 with high-
dose bolus IL-2– this series included 149 
patients with renal cell carcinoma.  
Patients received IL-2 at the dose of 
720,000 international units per kilogram 
intravenously every 8 hours for a 
maximum of 15 doses per cycle: 2 cycles 
constituted a course of therapy.  Patients 
who showed response or stable disease 
after the first course went on to receive 
additional therapy.  An overall response of 
20% (CR+PR) was observed in patients with 
renal cell carcinoma, 7% (n=10) achieved 
complete response, and 13% (n=20) had a 
partial response.  With the exception of one 
complete responder who had liver 
metastases, all others had lung metastases 
or involvement of lymph nodes.  The 
responses were noted to be durable and 
ongoing at up to 76 months in the patients 
with a complete response, and 69 months 
in those with a partial response at the time 
of publication.  There were 3 (1.1%) 
treatment-related deaths; 2 due to 
myocardial infarction and one as a result of 
sepsis (18).  
Some of the selected trials using high-dose 
IL-2 are summarised in Table 1. A large 
additional series published by Fyfe et al. 
reported the outcomes of 255 patients with 
advanced renal cell carcinoma treated with 
high-dose bolus IL-2 enrolled in 7 phase II 
studies at 21 institutions.  Two of these 
studies used the dose of 720,000 
international units per kilogram while the 
other 5 used the dose of 600,000 
international units per kilogram 
administered every 8 hours over 15 
minutes for a total of 14 doses per cycle.  
Responses were observed in 37/255 
patients (15%); 17 (7%) patients achieved a 
complete response and 20 patients (8%) a 
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     Table 1. High dose interleukin-2 in advanced RCC 
Study N Dose ORR 
Response Duration 
(Months) 
Ref. 
7 phase II 
studies 
 
255 600,000-720,000 IU/kg 
ORR*= 15% 
CR= 7% 
PR= 8% 
54  (3 to 131+) 
80+ (7 to 131+) 
20 (3 to 126+) 
(19,20) 
NCI experience 
Single 
Institution 
 
259 720,000IU/kg 
20% 
CR=9% 
PR =11% 
21 CR median 
survival not reached 
– 221+ 
(21) 
Phase II 
“SELECT” study 
 
120 600,000IU/kg 29% 
20 responders (4 to 
35+) 
(22) 
     * CR, complete response; ORR, overall response rate; PR, partial response 
 
 
partial response. The updated median 
duration of response for all patients was 54 
months.  The median duration for those 
with complete response had not been 
reached at the time of reporting: it was at 
least 18 months with a range of 7 to 
greater than 131 months.  The median 
duration of response for the patients who 
had a partial response was 20 months with 
a range of 3 to greater than 126 months.  
Eleven (4%) out of 255 patients died of 
treatment-related toxicity (6 patients had a 
myocardial infarction or respiratory failure, 
3 had gastrointestinal toxicity, one had 
sepsis and one died at home of unknown 
causes) (19, 20).  
 
Klapper et al. reported the expanded NCI 
Surgery Branch experience for 259 patients 
with advanced renal cell carcinoma who 
were treated between 1986 and 2006 with 
high-dose IL-2 at the dose of 720,000 units 
per kilogram IV bolus every 8 hours up to a 
total of 15 doses per cycle (later reduced to 
a maximum of 12 doses). Response was 
evaluated using the WHO criteria initially 
and RECIST criteria since 1998.  An overall 
objective response rate of 20% was 
observed (consistent with previous reports); 
9% (23/259) of patients achieved a 
complete response and 12 % (30/259) of 
patients had a partial response.  Median 
survival for the partial responders was 39.1 
months and had not been reached for the 
complete responders at the time of 
analysis.  There were 2 treatment-related 
deaths in the earlier part of the study (21).  
In an effort to optimize IL-2 therapy, the 
renal cell “SELECT” trial was designed to 
assess if the patient population could be 
selectively enriched based on carbonic 
anhydrase IX overexpression within the 
tumor besides other factors.  Of the 120 
patients treated in this study, 96% had 
clear cell histology and 99% had 
nephrectomy.  Patients received high-dose 
IL-2 at the dose of 600,000 international 
units per kilogram every 8 hours.  The 
overall response rate was 29% (35/120): 
the response rate for clear cell histology 
was 30% (35/115).  A complete response 
was observed in 7 patients, while 28 
patients had a partial response.  Although 
no correlation was noted with carbonic 
anhydrase IX expression, clear cell 
histology appeared to be important given 
the higher than historically observed 
response rates (22).  
High dose vs/or low dose IL-2  
Despite the durable responses elicited by 
high-dose IL-2 that may translate into 
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Table 2. High dose interleukin-2 vs/or low dose interleukin-2 in advanced RCC 
Study N Dose ORR 
Response 
Duration (months) 
Ref. 
Randomized  
 
CIV* IL2 
 
SC IFN α 
 
CIV IL2 + SC IFN α 
 
 
 
138 
 
147 
 
140 
 
 
18x106 IU/m2/d CIVx5d  
 
18x106 IU/d sc 3x/w 
 
18x106 IU/m2/d CIVx5d  
+ IFN 6x106 sc 3x/w 
 
 
6.5% 
 
7.5% 
 
18.6% 
 
 
Median OS 12 
 
Median OS 13 
 
Median OS 17 
(23) 
Randomized  
 
High dose bolus IL2 
 
 
 
Low dose bolus IL2 
 
 
 
155 
 
 
 
149 
 
 
720,000 IU/kg 
 
 
 
72,000IU/kg 
 
 
21% 
(CR=11, 
PR=22) 
 
13% 
(CR=6, 
PR=13) 
 
 
8/11 ongoing CR at 
9.3 yrs 
 
 
3/6 ongoing CR at 
10.1 yrs 
(24) 
Randomized 
 
High dose bolus IL2 
 
 
 
SC Low dose IL2  
+ 
IFN 
 
 
 
95 
 
 
 
91 
 
 
600,000IU/kg 
 
 
 
IL2 5x106 IU/m2 q8hr d1 
Then 5x106IU/m2 qd x4d 
 + IFN 5x106IU/m2 3x/w 
 
 
23.2% 
(CR=8) 
 
 
9.9% 
(CR=3) 
 
 
14 (10/22 free of 
progression at 3 
years) 
 
7 (3 pts free of 
progression at 3 
years 
(25) 
Randomized 
 
Medroxyprogesterone 
 
SC IFN 
 
SC Low dose IL2 
 
 
 
SC IFN + IL2 
 
 
 
123 
 
122 
 
125 
 
 
 
122 
 
 
200 mg orally every day 
 
9x106 IU 3x/w 
 
9x106 IU bid x 5d week 1 
9x106 IU bid x 2d then 
9x106 IU q d x 3d, w2-4 
 
IL2 and IFN schedule as 
above; IFN dose 6x106IU 
 
 
2.5% 
 
4.4% 
 
4.1% 
 
 
 
10.9% 
 
 
Median OS 14.9  
 
Median OS 15.2 
 
Median OS 15.3 
 
 
 
Median OS 16.8 
(26) 
*CIV, intravenous; CR, complete response; ORR, overall response rate; OS, overall survival;  
PR, partial response; Sc, subcutaneous 
 
 
 
“cure” for some, its use is restricted to 
selected individuals with good organ 
function and performance status. Wider 
applicability is limited due to significant 
toxicity in the form of a brisk capillary leak 
syndrome that can result in multi-organ 
system compromise, albeit rapidly 
reversible but requiring intense monitoring 
and trained personnel in place.  Efforts 
have therefore been made to study the 
efficacy of IL-2 at lower doses in the hope 
that treatment might be safer and easier to 
administer to a broader patient base.  
Some of the selected trials using low-dose 
IL-2 and comparing them to high-dose 
regimens are discussed (Table 2).  
 
In that vein, Negrier et al. reported 425 
patients with metastatic renal cell 
carcinoma, randomized to receive IL-2 as a 
continuous intravenous infusion or 
interferon alpha 2a or the combination of 
both (23). In the IL-2 monotherapy arm 
induction phase, drug was administered at 
the dose of 18 million international units 
per square meter of body surface area per 
day for 5 days repeated twice with a 6-day 
break.  In the maintenance phase, the 
same dose was repeated every 3 weeks.  In 
the interferon monotherapy arm, drug was 
administered at the dose of 18 million 
international units subcutaneously 3 times 
a week for 10 weeks as induction and 13 
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additional weeks as maintenance.  In the 
combination arm, IL-2 was administered at 
full dose (as above) but interferon alpha 2a 
was administered at the dose of 6 million 
international units 3 times a week during 
IL-2 dosing.  The response rates were 6.5% 
for low dose IL-2 monotherapy, 7.5% for 
interferon alpha 2a monotherapy and 
18.6% for the combination.  There was no 
significant difference in overall survival, 
and toxicity was greater in the IL-2 
containing arms.  
 
The Surgery Branch at the NCI conducted 
a 3 arm randomized study comparing high-
dose IL-2 to two different low-dose IL-2 
regimens (24).  A total of 156 patients were 
assigned to the high-dose arm and received 
IL-2 at the dose of 720,000 international 
units per kilogram IV bolus every 8 
hours.150 patients received low-dose IL-2 
at the dose of 72,000 international units 
per kilograms IV bolus every 8 hours, while 
94 patients in the third arm received daily 
subcutaneous low-dose IL-2. The response 
rate in the high-dose arm was 21%, 13% in 
the low-dose intravenous arm, and 10% in 
the daily subcutaneous.  There were no 
treatment-related deaths. Toxicities, 
especially hypotension, were less frequent 
in the low-dose arms.  Durable responses 
were noted in all arms: 8/11 patients who 
achieved a complete response in the high-
dose arm were noted to have an ongoing 
response at 9.3 years. Three of the 6 
patients who achieved complete response 
in the low-dose intravenous arm were 
noted to have ongoing response at 10.1 
years and one complete response in the 
subcutaneous low-dose arm had an 
ongoing response past 78 months at the 
time of analysis.  
 
The Cytokine Working Group further 
conducted a randomized phase III study to 
compare high-dose IL-2 with the 
combination of low-dose subcutaneous - 
IL-2 and interferon (25).  In this study 91 
patients received outpatient subcutaneous 
IL-2 at a loading dose of 5 million units per 
body meter squared every 8 hours for 3 
doses on day 1 followed by 5 million units 
per meter squared on days 2, 3, 4 and 5 
during the first week and then 5 million 
units per body meter squared for 5 days 
every week for 3 weeks.  In addition these 
patients received interferon at the dose of 5 
million units per meter squared thrice 
weekly for 4 weeks.  A total of 95 patients 
were treated on the high-dose intravenous 
IL-2 arm and received 600,000 units per 
kilogram IV bolus every 8 hours for a 
maximum of 14 doses.  An overall response 
of 23.2% (22/95) was observed in the high-
dose intravenous IL-2 arm compared to 
9.9% (9/91) in the low-dose subcutaneous 
IL-2 plus interferon arm.  Eight patients 
achieved a complete response in the high-
dose intravenous IL-2 arm; this response 
was durable in 7/8 patients at 3 years.  
Three of 9 responding patients achieved a 
complete response in the low-dose 
subcutaneous IL-2 plus interferon arm, but 
all of them had recurrence of disease 
within 3 years.  
The French immunotherapy intergroup 
conducted a randomized trial to compare 
low dose subcutaneous IL-2,  interferon 
alpha 2a, the combination of  the 2 
cytokines and medroxyprogesterone in 492 
patients with metastatic renal cell 
carcinoma of intermediate prognosis (26).  
Intermediate prognosis was defined by 
requiring a Karnofsky score of ≥80% if 
metastases in more than one organ; 
Karnofsky score of 80% if metastases in 
one organ; normal blood, liver and renal 
function.  Patients with prior treatment, 
evidence of brain metastasis, uncontrolled 
cardiac issues, active infections or who 
were on corticosteroids were excluded.  
Subcutaneous IL-2 was administered at the 
dose of 9 million international units every 
day to 125 patients. 122 patients received 
interferon alpha 2a at the dose of 9 million 
international units 3 times a week. 122 
patients received both interferon and IL-2 
at the above doses, and 123 patients 
received medroxyprogesterone acetate at 
the dose of 200 mg every day.  The 
response rate was 3.3% in the IL-2 arm, 
3.5% in the interferon arm, 10.9% in the 
cytokine combination arm, and 1.7% in the 
medroxyprogesterone arm.  No differences 
were noted in the progression-free survival 
or overall survival amongst all the arms.  
High Dose IL-2 – Contemporary 
Experience: “PROCLAIM”  
Based on the relatively poor results 
associated with low-dose IL-2 high-dose IL-
2 has generally come to be accepted as the 
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standard of care for properly selected 
patients. Since the early trials that led to 
the approval of high dose IL-2, centers of 
excellence have developed treatment 
schema that can greatly reduce toxicities.  
Mitigation strategies and guidelines to 
safely administer high-dose interleukin-2 
have since been developed and used 
effectively (27). Data from contemporary 
single-institution/group series show that 
high-dose IL-2 can be administered safely 
at centers with adequate experience and 
careful selection of patients.  At the Levine 
Cancer Institute, we have treated 104 
patients with advanced renal cell 
carcinoma with high-dose IL-2. The 
response rate has been 26% including 8 
complete and 19 partial responses.  Five of 
the 8 complete responders have an ongoing 
response at 122 months.   There has been 
no treatment-related mortality (28).   
Roswell Park Cancer Institute reported 
their experience for 91 patients who were 
treated with high-dose IL-2. The overall 
response rate was 16% with no treatment-
related mortality (29). Payne et al. reported 
the experience from the Earle A Chiles 
Research Institute for 186 patients with 
advanced renal cell cancer treated with 
high-dose IL-2.  The overall response rate 
was 24% with treatment-related mortality 
of less than 1% (30). The numbers treated 
at individual centers are however modest, 
making these non-systematic reviews 
difficult to interpret.  In order to capture 
the contemporary experience more 
effectively, a high-dose IL-2 registry was 
established incorporating 35 centers in the 
USA (31). PROCLAIM (Proleukin® 
Observational Registry to Evaluate the 
Treatment Patterns and Clinical Response 
in Malignancy) is designed to create a 
robust observational database of real world 
contemporary high-dose IL-2 experience.  
The goals of the PROCLAIM registry are to: 
(i), provide information regarding IL-2 and 
its prospective use; (ii), compare the 
difference in administration approaches for 
their respective effect on outcomes; (iii), 
validate efficacy of high-dose IL-2 on 
response and survival in the treatment of 
malignant diseases; (iv), identify patients 
and site-specific prognostic factors and (v), 
study and potentially guide the emergence 
of new therapeutic options in the 
immunological armamentarium. 
The registry started enrolling the 
prospective cohort in September 2011; data 
for a retrospective cohort was collected 
between January 2007 and February 2012.  
Despite the compelling high dose IL-2 data, 
many oncologists now employ targeted 
therapy with suppression of the VEGF or 
mTOR pathways as initial therapy in 
patients with advanced renal cell 
carcinoma.  Retrospective reports with 
small numbers of patients treated with 
high-dose IL-2 after treatment with 
targeted therapy suggest higher than 
expected cardiovascular toxicity (some 
quite profound including cerebral 
vasculitis) if patients have previously 
received VEGF-targeted therapy (32).  The 
PROCLAIM registry was queried to address 
the question of optimal sequencing of IL-2 
therapy with targeted therapy.  
Observations from the retrospective data 
cohort presented by Morse et al. (33) 
showed the median overall survival for 
patients (n=82) who received high-dose IL-2 
as initial systemic treatment to be 61.8 
months compared to 48 months for those 
(n=15)  who had received targeted therapy 
prior to high-dose  (IL-2).  While not 
conclusive, this observation suggests 
superior results in patients treated with 
high dose IL2 as first line therapy. 
Discussion 
Immunotherapy with high-dose IL-2 had 
been the mainstay of systemic treatment 
for advanced renal cell carcinoma until the 
development of agents inhibiting the VEGF 
and mTOR pathways.  VEGF TKIs 
(sunitinib, pazopanib, axitinib, sorafenib), 
mTOR inhibitors (temsirolimus, everolimus) 
and the combination of bevacizumab plus 
interferon have been approved for 
treatment of patients with metastatic renal 
cell carcinoma by the US FDA (34).  
Availability of these agents has had an 
impact on the natural history of the disease 
with prolongation of median survival to 22 
months (35).  Durable long-term responses 
observed with immunotherapy have, 
however, rarely been reported with these 
agents.  
Given that treatment with high-dose IL-2 is 
not applicable for many patients with 
advanced renal cell carcinoma, new 
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immunotherapeutic approaches are being 
investigated. Nivolumab is a fully human 
antibody that binds to PD-1, an immune 
inhibitory checkpoint expressed on the 
surface of T cells.  Binding of the anti-PD-1 
antibody to PD-1 blocks the interaction 
with its ligands PD-L1 and PD-L2 and 
prevents the T effector cell from switching 
off (36, 37).  A phase II trial of nivolumab 
monotherapy in patients with metastatic 
enal cell carcinoma showed an overall 
response rate of 20% (using RECIST 
criteria v1.1) in heavily pretreated patients 
who had received up to 3 prior lines of 
treatment.  The median overall survival for 
patients having received more than 2 lines 
of prior treatment was 18.7 months and 
was not reached in patients who had 
received one prior line of therapy.  Almost 
one third of the responding patients 
showed ongoing responses beyond 24 
months.  Patients’ overall tolerance was 
reported to be good with grade 3-4 
treatment-related ‘select’ events (defined as 
having potential immunologic etiology that 
require frequent monitoring and/or unique 
intervention) observed in less than 5% of 
the patients (38).  
Hammers et al. presented data from a 
phase I study with the combination of 
nivolumab plus ipilimumab in patients 
with metastatic renal cell carcinoma.  
Ipilimumab is a fully humanized IgG1 
antibody that binds to the immune 
inhibitory checkpoint CTLA-4. Binding of 
anti-CTLA-4 antibody to CTLA-4 expressed 
on the surface of activated T cells prevents 
the T cell from switching off (39).  
Ipilimumab has been approved for 
treatment of patients’ metastatic melanoma 
(34).  Almost 80% of the patients in the 
study had received at least one prior line of 
treatment prior to receiving the 
combination.  The overall response rate for 
nivolumab at 3mg/kg and ipilimumab 1 
mg/kg was 43%: 78% of the responders 
had ongoing responses at the time of 
analysis (24 weeks).  The combination of 
the two drugs was tolerated well with 
treatment-related ‘select’ adverse events 
(defined as above) observed in less than 5% 
of the patients (40).  Amin et al. reported 
data for the phase I study with the 
combination of nivolumab with either 
sunitinib or pazopanib in patients with 
metastatic renal cell carcinoma.  The 
overall response rate was 52% and 45% in 
the sunitinib and pazopanib combination 
arms respectively.  While there were no 
treatment-related deaths, 82% in the 
sunitinib arm and 70% in the pazopanib 
arm experienced grade 3-4 treatment-
related toxicities (41).  These 
immunotherapeutic approaches hold great 
promise but mature data addressing the 
durability of these responses is awaited.  
Conclusion 
Where does standard high-dose 
interleukin-2 fit in clinical practice with 
currently available options?  The evidence 
demonstrates that properly selected 
patients with metastatic kidney cancer 
treated with IL-2 can be cured of their 
disease.  Administration of high-dose IL-2 
requires admission to hospital for one week 
at a time with close monitoring by a 
dedicated team.  During the course of 
treatment patients can have a flu-like 
syndrome and experience substantial grade 
3-4 toxicity secondary to capillary leak 
syndrome manifesting as hypotension, 
oliguria, generalized edema, tachy-
arrhythmias and hypoxemia.  These 
toxicities, however, occur in a monitored 
setting and are readily reversible.  As 
experience with high-dose IL-2 and 
management of its toxicities has matured, 
the incidence of treatment-related 
irreversible high-grade toxicity including 
death has been minimized, as evidenced by 
data being collected from experienced 
centers in the PROCLAIM registry.   
Mortality rates in experienced centers are 
less than 1%.  While the oral route of 
administration, non-life-threatening 
toxicities and broader applicability to most 
patients makes targeted therapies 
extremely desirable, daily dosing with 
ongoing side effects can significantly 
impact quality of life that needs to be 
balanced against the unlikely chance of a 
durable response.  Additionally the side 
effects that may include diarrhea, 
stomatitis, fatigue, cardiac toxicity, 
increased incidence of hemorrhagic and 
embolic phenomena, hand-foot skin 
syndrome, elevated triglyceride levels, 
hyperglycemia and noninfectious 
pneumonitis occur in the non-monitored 
environment.  Appropriate intervention for 
control of these symptoms is, therefore, 
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largely dependent on patient reporting and 
outpatient office response mechanisms.  
Emerging data for new immunotherapeutic 
modalities is extremely exciting and holds 
the promise of durable responses using 
agents administered in an outpatient 
setting, safely offered to a broad patient 
population.  Given the established 
durability of responses with high-dose IL-2 
and the ability to administer it safely at 
centers with experience, our institutional 
approach, supported by the NCCN 
guidelines (42), currently includes high-
dose IL-2 as first-line, potentially curative 
therapy. 
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